TCGA-CR-7368-01A-11R-2132-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.450
- MITOTIC_SPINDLE+0.390
- SPERMATOGENESIS+0.270
- KRAS_SIGNALING_DN+0.200
- IL6_JAK_STAT3_SIGNALING+0.180
- APICAL_SURFACE+0.170
- PI3K_AKT_MTOR_SIGNALING+0.170
- ESTROGEN_RESPONSE_LATE+0.160
- ESTROGEN_RESPONSE_EARLY+0.140
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.520
- MYC_TARGETS_V2-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- MYC_TARGETS_V1-0.330
- NOTCH_SIGNALING-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
- MYOGENESIS-0.270
- GLYCOLYSIS-0.230
- MTORC1_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-5153-01A-01R-1436-07 | — | — | 0.809 |
| 2 | SRR650133 | — | — | 0.793 |
| 3 | TCGA-CR-5249-01A-01R-1514-07 | — | — | 0.728 |
| 4 | 20ca78ce-1972-4f55-81f2-22683da33c66 | — | — | 0.728 |
| 5 | 0c5e45df-149d-4667-8154-312c5e6f246b | — | — | 0.724 |
| 6 | TCGA-CV-6939-01A-11R-1915-07 | — | — | 0.715 |
| 7 | TCGA-P3-A5QE-01A-11R-A28V-07 | — | — | 0.712 |
| 8 | SRR10899995 | — | — | 0.699 |
| 9 | SRR25043626 | — | — | 0.696 |
| 10 | SRR5088892 | — | — | 0.694 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |